Clinically applicable machine learning prediction model for pulmonary hypertension due to left heart disease Source: Virtual Congress 2021 – Non-pulmonary arterial hypertension pulmonary hypertension Year: 2021
Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes Source: Eur Respir J, 53 (3) 1802393; 10.1183/13993003.02393-2018 Year: 2019
Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes Source: Eur Respir J, 53 (3) 1801894; 10.1183/13993003.01894-2018 Year: 2019
Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis? Source: Eur Respir J 2016; 48: 1271-1273 Year: 2016
COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging Source: Eur Respir J, 52 (5) 1801570; 10.1183/13993003.01570-2018 Year: 2018
Using joint modelling to assess the association between a time-varying biomarker and a survival outcome: an illustrative example in respiratory medicine Source: Eur Respir J, 57 (2) 2003206; 10.1183/13993003.03206-2020 Year: 2021
How to better assess and predict disease progression and treatment response: home-based spirometry, biomarkers or …? Source: International Congress 2019 – High-tech in interstitial lung diseases: just hype and gadgets? Year: 2019
Towards individualised medicine for airways disease: identifying clinical phenotype groups Source: Eur Respir J 2012; 39: 1033-1034 Year: 2012
The heart rate variability analysis during a virtual reality exercise test Source: Virtual Congress 2021 – Hypoxia, exercise and respiratory function in pathophysiological conditions Year: 2021
The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm Source: Eur Respir J, 59 (2) 2102669; 10.1183/13993003.02669-2021 Year: 2022
The effects of virtual reality on pulmonary functions, functional level and pain in the early period after open heart surgery Source: Virtual Congress 2020 – Aspects of pulmonary rehabilitation: part 1 Year: 2020
Identification of lung transplant candidates, stratification of risk, lung allocation and quality control in Europe using real-time decision-making and big data: lessons learned and future perspectives Source: Virtual Congress 2021 – Lung graft allocation and monitoring in the 21st century Year: 2021
A network lung cancer pathway in review: Are we choosing the right diagnostic approach? Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010
COPD phenotypes and co-morbidities: to what extent do they affect a successful response to rehabilitation? Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011
Adding biological markers to COPD categorisation schemes: a way towards more personalised care? Source: Eur Respir J 2016; 47:1601-1605 Year: 2016
Healthy smokers at risk for cardiovascular disease: the usefullness of left ventricular function and metabolic status evaluation. Source: International Congress 2017 – Smoking and health hazards Year: 2017
Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow Source: Eur Respir J, 58 (2) 2102008; 10.1183/13993003.02008-2021 Year: 2021
Does a predominant clinical COPD phenotype predict different outcome responses to pulmonary rehabilitation? Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012
The battle of new biomarkers for right heart failure in pulmonary hypertension: is the queen of hearts NT-proBNP defeated at last? Source: Eur Respir J, 57 (4) 2004277; 10.1183/13993003.04277-2020 Year: 2021
Surrogate markers of right ventricular adaptation better predict long-term survival in patients with PAH than traditional prognostic variables Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013